Evidence map›Paper›PMID 30581056›Full record

ReviewTrends in endocrinology and metabolism: TEM2019

Identifying Potential Ageing-Modulating Drugs In Silico.

Handan Melike Dönertaş, Matías Fuentealba, Linda Partridge, Janet M Thornton

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Trends in endocrinology and metabolism: TEM, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.9field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. The quest to slow ageing through drug discovery.Nature reviews. Drug discovery · 2020
    Review
  12. Terpenoids as Potential Geroprotectors.Antioxidants (Basel, Switzerland) · 2020
    Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Handan Melike DönertaşEuropean Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Hinxton CB10 1SD, UK; These authors contributed equally to this work.
Matías FuentealbaEuropean Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Hinxton CB10 1SD, UK; Institute of Healthy Aging, Department of Genetics, Evolution and Environment, University College London, London, UK; These authors contributed equally to this work.
Linda PartridgeInstitute of Healthy Aging, Department of Genetics, Evolution and Environment, University College London, London, UK; Max Planck Institute for Biology of Aging, Cologne, Germany.
Janet M ThorntonEuropean Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Hinxton CB10 1SD, UK. Electronic address: thornton@ebi.ac.uk.
European Bioinformatics Institute · GBUniversity College London · GB

Funding

Wellcome Trust
6 · The paper itself

Abstract

Increasing human life expectancy has posed increasing challenges for healthcare systems. As people age, they become more susceptible to chronic diseases, with an increasing burden of multimorbidity, and the associated polypharmacy. Accumulating evidence from work with laboratory animals has shown that ageing is a malleable process that can be ameliorated by genetic and environmental interventions. Drugs that modulate the ageing process may delay or even prevent the incidence of multiple diseases of ageing. To identify novel, anti-ageing drugs, several studies have developed computational drug-repurposing strategies. We review published studies showing the potential of current drugs to modulate ageing. Future studies should integrate current knowledge with multi-omics, health records, and drug safety data to predict drugs that can improve health in late life.

Indexed as

AgingAnimalsHumansLife ExpectancyLongevityageingcomputational biologydrug repurposinglongevity

Identifiers

PMID30581056
PMCPMC6362144
OpenAlexW2906477884

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.